Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (1-10 of 282) with videos related to

Pageof 29
Sort By:
Journal of Biometrics & Biostatistics|January 28, 2014
Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary EndpointsSusan Halabi
Urologic Oncology|May 3, 2008
Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancerSusan Halabi
Pharmaceutical Statistics|April 15, 2021
A semiparametric modeling approach for analyzing clinical biomarkers restricted to limits of detectionSandipan Dutta, Susan Halabi
Chance (New York, N.Y.)|April 17, 2026
Advancing Precision Oncology Through Biomarker Driven Trials: Theory vs. PracticeSusan Halabi, Donna Niedzwiecki
Diagnostic and Prognostic Research|November 6, 2018
Combined Performance of Screening and Variable Selection Methods in Ultra-High Dimensional Data in Predicting Time-To-Event OutcomesLira Pi, Susan Halabi
NEJM Evidence|February 6, 2024
Randomized Phase I Trials - One Size Fits All?Susan Halabi, Codruta Chiuzan
Biomed Research International|September 7, 2016
High Dimensional Variable Selection with Error ControlSangjin Kim, Susan Halabi
European Urology|July 1, 2025
How To Interpret Subgroup Analyses from Prospective Randomized Clinical Trials: What Clinicians Need To KnowSusan Halabi, Siyuan Guo
Urologic Oncology|January 30, 2015
Independent data monitoring committees: an update and overviewOliver Sartor, Susan Halabi
Seminars in Oncology|May 25, 2010
The importance of identifying and validating prognostic factors in oncologySusan Halabi, Kouros Owzar
Pageof 29

Showing results (1-10 of 282) with videos related to

Sort By:
Pageof 29
Journal of Biometrics & Biostatistics|January 28, 2014
Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary EndpointsSusan Halabi
Urologic Oncology|May 3, 2008
Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancerSusan Halabi
Pharmaceutical Statistics|April 15, 2021
A semiparametric modeling approach for analyzing clinical biomarkers restricted to limits of detectionSandipan Dutta, Susan Halabi
Chance (New York, N.Y.)|April 17, 2026
Advancing Precision Oncology Through Biomarker Driven Trials: Theory vs. PracticeSusan Halabi, Donna Niedzwiecki
Diagnostic and Prognostic Research|November 6, 2018
Combined Performance of Screening and Variable Selection Methods in Ultra-High Dimensional Data in Predicting Time-To-Event OutcomesLira Pi, Susan Halabi
NEJM Evidence|February 6, 2024
Randomized Phase I Trials - One Size Fits All?Susan Halabi, Codruta Chiuzan
Biomed Research International|September 7, 2016
High Dimensional Variable Selection with Error ControlSangjin Kim, Susan Halabi
European Urology|July 1, 2025
How To Interpret Subgroup Analyses from Prospective Randomized Clinical Trials: What Clinicians Need To KnowSusan Halabi, Siyuan Guo
Urologic Oncology|January 30, 2015
Independent data monitoring committees: an update and overviewOliver Sartor, Susan Halabi
Seminars in Oncology|May 25, 2010
The importance of identifying and validating prognostic factors in oncologySusan Halabi, Kouros Owzar
Pageof 29